Atux Iskay is developing small molecule modulators of the tumor suppressor phosphatase Protein Phosphatase 2A (PP2A). Firm's currently active therapeutic areas are in oncology, neurodegenerative disease and respiratory disease. The therapeutic mechanism, normalization of PP2A function, and the in vitro and in vivo effects of our prototype and next generation PP2A activators fit the operational definition of senotherapeutic and the technology has the potential to impact human health in a broad and significant way. Atux Iskay is happy to provide samples of public domain PP2A activator compounds to academic researchers with a view to establishing collaborations and publication. At the present time company would particularly like to hear from researchers in aging and metabolic disease/diabetes fields.
